Switch theme
Sign up to access all valuation multiples
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
2010
23
LTM Revenue $4.0M
LTM EBITDA n/a
$70.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Outlook Therapeutics has a last 12-month revenue of $4.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Outlook Therapeutics achieved revenue of n/a and an EBITDA of -$72.1M.
Outlook Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Outlook Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$57.4M | -$72.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$66.1M | -$59.0M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | $12.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Outlook Therapeutics's stock price is $1.
Outlook Therapeutics has current market cap of $45.3M, and EV of $70.7M.
See Outlook Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70.7M | $45.3M | XXX | XXX | XXX | XXX | $-2.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Outlook Therapeutics has market cap of $45.3M and EV of $70.7M.
Outlook Therapeutics's trades at 17.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Outlook Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Outlook Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $70.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOutlook Therapeutics's NTM/LTM revenue growth is 523%
Outlook Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.1M for the same period.
Over next 12 months, Outlook Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Outlook Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Outlook Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Outlook Therapeutics acquired XXX companies to date.
Last acquisition by Outlook Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Outlook Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Outlook Therapeutics founded? | Outlook Therapeutics was founded in 2010. |
| Where is Outlook Therapeutics headquartered? | Outlook Therapeutics is headquartered in United States of America. |
| How many employees does Outlook Therapeutics have? | As of today, Outlook Therapeutics has 23 employees. |
| Who is the CEO of Outlook Therapeutics? | Outlook Therapeutics's CEO is Mr. Lawrence A. Kenyon. |
| Is Outlook Therapeutics publicy listed? | Yes, Outlook Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Outlook Therapeutics? | Outlook Therapeutics trades under OTLK ticker. |
| When did Outlook Therapeutics go public? | Outlook Therapeutics went public in 2016. |
| Who are competitors of Outlook Therapeutics? | Similar companies to Outlook Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Outlook Therapeutics? | Outlook Therapeutics's current market cap is $45.3M |
| What is the current revenue of Outlook Therapeutics? | Outlook Therapeutics's last 12-month revenue is $4.0M. |
| What is the current EV/Revenue multiple of Outlook Therapeutics? | Current revenue multiple of Outlook Therapeutics is 17.9x. |
| Is Outlook Therapeutics profitable? | Yes, Outlook Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
